Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 5/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063500 | 0.84 | SCN9A (0.47) | SCN9A | |
| SCHEMBL23140809 | 0.82 | SCN9A (0.48) | SCN9AFFAR1CETPMGLLHCRTR2 | |
| SCHEMBL23638940 | 0.82 | SCN9A (0.51) | SCN9AFFAR1HCRTR2 | |
| SCHEMBL23638885 | 0.81 | SCN9A (0.42) | SCN9ACETP | |
| SCHEMBL23638884 | 0.81 | SCN9A (0.34) | SCN9ACETP | |
| SCHEMBL23638939 | 0.81 | SCN9A (0.48) | SCN9AFFAR1CETPMGLLHCRTR2 | |
| SCHEMBL23639104 | 0.80 | SLC6A2 (0.40) | SCN9A | |
| SCHEMBL20063488 | 0.79 | SCN9A (0.53) | SCN9AHCRTR2 | |
| SCHEMBL20096086 | 0.78 | SCN9A (0.42) | SCN9AFFAR1CETPMGLLHCRTR2 | |
| SCHEMBL20096261 | 0.78 | SCN9A (0.42) | SCN9AFFAR1CETPMGLLHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, CACNA1A, SCN1A | SCN9A 34/4885FFAR1 1643/4885CETP 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.